How Much Participant Payment Is Too Much?

Is There a Maximum Amount Researchers Can Pay Participants?

You plan to pay participants $20. That seems modest. What about $100? $500? $1,000?

At some point, researchers often assume, the amount must become ethically "too much." The difficulty is finding that point.

Major research-ethics guidance does not provide a universal monetary ceiling for participant payment. An amount cannot be judged simply by looking at the number. A payment that appears substantial for a short questionnaire may be entirely different from compensation associated with repeated visits, considerable time, travel, inconvenience, or demanding procedures.

The more useful question is therefore not "What is the maximum allowed?" but "What is this payment for, and what effect might this particular payment arrangement have in this particular study?"

There Is No Universal Ethical Maximum

Why There Is No Simple Maximum Payment

The Number Alone Tells You Surprisingly Little

Suppose two studies each offer $300.

In one study, participants complete a 15-minute questionnaire. In another, they make six research visits, spend many hours completing procedures, and incur substantial inconvenience. Calling $300 "high" without considering those differences misses most of the ethical analysis.

FDA guidance therefore asks IRBs to review both the amount and the schedule of participant payments rather than prescribing a universal maximum. OHRP-related guidance likewise emphasizes that influence is contextual and that there are no clear-cut monetary boundaries separating appropriate from inappropriate influence.

The first step is to determine what the payment is supposed to compensate for. Only then can its size be evaluated meaningfully.

Break the Total Payment Into Its Actual Functions

A headline figure can be misleading because the total may combine several ethically different payments.

A $500 total that includes substantial travel reimbursement and compensation accumulated across many visits should not automatically be evaluated in the same way as a $500 bonus offered solely for completing a brief study. The purpose of each part of the payment matters.

Fair Compensation Does Not Become Unethical Merely Because the Total Is Large

Long or demanding studies can produce large total payments simply because participants contribute a great deal.

SACHRP's 2019 recommendations argue that fair compensation for participants' time and effort should not itself be regarded as undue influence. Compensation may help offset opportunity costs and acknowledge the burdens participants undertake. The recommendations similarly treat reasonable reimbursement differently from incentive payments.

This matters because an overly cautious payment ceiling can produce an odd result: the longer and more demanding the study becomes, the less fairly participants can be compensated because researchers fear that the accumulated total "looks too high."

The ethical objective is not automatically to minimize payment. It is to make the payment defensible.

Incentive Payments Require a Different Question

An incentive deliberately provides an additional reason to participate or remain enrolled. Here, size may matter more directly.

SACHRP explains that concern can increase as the net benefit of an incentive grows or as payment becomes more contingent on completing participation. The issue is not simply that the participant likes the offer. Incentives are supposed to be attractive.

The concern is whether consideration of the incentive could overwhelm adequate consideration of study risks, burdens, discomforts, or other important features. That is the point at which the analysis moves from "large payment" toward possible undue influence.

A Payment Can Be Very Attractive Without Automatically Invalidating Consent

Imagine a participant who says, "I would never do this study for $20, but for $300 I would."

That statement does not establish undue influence. It establishes influence.

SACHRP explicitly argues that a person may be strongly motivated by money and still make an informed and voluntary decision. A participant might carefully understand the study, dislike some of its burdens, decide that the payment makes those burdens worthwhile, and enroll.

The ethical problem is more specific: has the offer impaired the person's adequate consideration or understanding of what participation entails?

There Is No Ethical Rule That Poorer Participants Must Be Offered Less

Researchers may worry that a payment that seems ordinary to a high-income participant could be highly attractive to someone with fewer financial resources. That observation is relevant, but it does not establish that the lower-income participant has lost decision-making capacity or should receive less.

SACHRP cautions against assuming that incentive payments compromise decision-making simply because prospective participants are economically disadvantaged. Restricting payments on that basis can become paternalistic and may create justice concerns of its own.

It can also produce a paradox. If payment is deliberately kept very low, the amount may still attract participants who urgently need money while excluding people for whom the payment no longer makes participation worthwhile. Lowering payment does not necessarily remove the ethical concern researchers thought they were solving.

Large Payment Is Not the Same as Coercion

Payment and coercion are often casually conflated.

The Belmont Report describes coercion in terms of an overt threat of harm used to obtain compliance. SACHRP similarly emphasizes that a genuine offer of payment to which a person is not otherwise entitled does not ordinarily constitute coercion.

A large payment may raise questions about influence. It does not become a threat merely because the amount is large. The distinction between large payment and coercion is therefore conceptually important.

How Payment Is Scheduled Can Matter as Much as the Total

Consider two studies that each offer participants a total of $500.

Study A pays compensation as participants complete each visit. Study B tells participants that they receive nothing unless they complete every visit.

The total is identical. The pressure created by the payment structure is not.

FDA guidance states that payment credit should accrue as a study progresses and generally should not be contingent on completing the entire study. It allows a small completion incentive when reasonable, provided that the bonus is not so large that it unduly induces participants to remain when they otherwise would withdraw.

This is why decisions about prorating participant payment should be part of the payment design rather than an administrative afterthought.

Payment Cannot Rescue an Unacceptable Study

There is another boundary that no payment amount can cross.

FDA does not treat participant payment as a research benefit when weighing the risks and benefits of a study. OHRP-related guidance similarly states that remuneration should not be used to offset research risks in deciding whether research should be approved.

If the study is ethically unacceptable without a large payment, increasing the payment does not solve the underlying problem. Payment can make acceptable participation more attractive. It cannot purchase ethical permission for unacceptable research.

Is $500 Too Much to Pay a Participant?

This example does not establish that Study B's payment is necessarily unethical. It shows why "$500 is too much" cannot be the conclusion without further analysis. The ethics committee would need to consider what the offer is doing and whether the consent process adequately protects voluntary, informed decision-making.

Common Mistakes When Deciding Whether Payment Is Too High

Evaluate the Payment Before Deciding Whether It Is Too Much

Instead of searching for a universal maximum, build an auditable rationale for the payment. That gives an ethics committee something more informative than intuition about whether the number "feels high."

A high number may ultimately require modification. But "high" is a description, not yet an ethical diagnosis.

Before Deciding That Participant Payment Is Too High

Frequently Asked Questions About Participant Payment Amounts

There Is No Magic Number Where Payment Becomes Too Much

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.